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Abstract Anandamide is an endogenous ligand for A9-tetrahy- 
drocannabinol (THC) receptors. Incubation of cultured cells with 
anandamide or THC causes increased arachidonic acid release 
and eicosanoid biosynthesis. Here we demonstrate that the MAP 
kinase signal transduction pathway contributes to this response. 
Treatment of WI-38 fibroblasts with anandamide causes in- 
creased MAP kinase activity and increased phosphorylation of 
the arachidonate-specific cytoplasmic phospholipase A 2 (cPLA2). 
Significantly, MAP kinase phosphorylates and activates cPLA2 
[Lin, et al., Cell, 72 (1993) 269-2781. The MAP kinase signal 
transdnction pathway may therefore mediate the effects of ana- 
damide on cPLA2 activation and arachidonic acid release. 
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1. Introduction 
The major active constituent of marijuana, A9-Tetrahydro - 
cannabinol (THC), and its derivatives have potential clinical 
use because these drugs cause analgesia, immunosuppression, 
and reduced nausea in addition to psychoactive effects [1,2]. 
The actions of THC are thought o be mediated, in part, by 
specific receptors that are expressed on the surface of respon- 
sive cells. Two proteins with seven transmembrane-spanning 
domains typical of G protein-coupled receptors have been iden- 
tified as putative THC receptors by molecular cloning [3,4]. The 
existence of receptors for the drug THC suggests that a physi- 
ologically relevant ligand may exist. This possibility has re- 
cently been confirmed by the identification of arachidonyletha- 
nolamide (anandamide) as an endogenous cannabimimetic hat 
binds and activates THC receptors [5]. It is therefore likely that 
anandamide is an important regulatory molecule. However, the 
physiological role of anandamide has not been established. 
The results of previous tudies have indicated that the mech- 
anism of signal transduction by cannabinoids may be mediated, 
in part, by cAMP accumulation and an inhibition of N-type 
Ca z+ channels [6-12]. However, it has also been proposed that 
several actions of cannabinoids may result from the increased 
level of tissue icosanoids that occur in humans and experimen- 
tal animals treated with cannabinoids [2]. These include the 
effect of THC on time estimation, heart-rate acceleration, and 
the subjective 'high' in humans; the induction of catalepsy in 
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mice; and the hypotensive r sponse in dogs [2]. The increased 
level of eicosanoids has been attributed to the ability of can- 
nabinoids to mobilize arachidonic acid from cellular phospho- 
lipid storage sites by activation of phospholipase A 2 (PLA2), 
whereupon it is rapidly metabolized into various eicosanoids 
[13,14]. Although evidence has been presented indicating that 
the brain-type THC receptor does not mediate arachidonic acid 
release when expressed in Chinese hamster ovary cells [10], 
THC-induced release of arachidonic acid is receptor-mediated 
in mouse peritoneal cells [15]. 
Recently, a hormonally-responsive, arachidonic acid-spe- 
cific, cytoplasmic PLA2 (cPLA2) has been identified by molecu- 
lar cloning [16,17]. We have demonstrated that cPLA2 is 
phosphorylated and activated by MAP kinase [18]. The identi- 
fication of cPLA 2 as a target of the MAP kinase signal 
transduction pathway [19] suggests a possible mechanism of 
signaling by cannabinoids. Here, we demonstrate hat the en- 
dogenous cannabinoid anandamide activates cPLA2 and 
eicosanoid production via the MAP kinase signal transduction 
pathway. 
2. Materials and methods 
2.1. Tissue culture 
WI-38 human fetal ung fibroblasts (American Type Culture Collec- 
tion, passage 17-21) were cultured in modified Eagle's medium supple- 
mented with 10% fetal bovine serum (Gibco-BRL). 
2.2. Arachidonic acid release 
The release of [3H]arachidonic acid (and metabolites) was measured 
as described by Lin et al. [18] Briefly, the cells were seeded into 12-well 
dishes, grown to conftuency and then incubated for 18 h with 0.5/.tCi 
of [3H]arachidonic acid (Dupont-NEN) in 0.5 ml of serum-free modi- 
fied Eagle's medium. The cell monolayers were rinsed three times with 
Krebs-Ringer HEPES-buffered saline containing 0.1% bovine serum 
albumin (KRH/BSA) and pre-incubated for 30 min at 37°C. The ceils 
were then incubated with KRH/BSA (0.5 ml) together with the indi- 
cated concentrations of agonists (5/.tl) for 10 min. The medium was 
removed and the released radioactivity was measured by liquid scintil- 
lation counting. PGE~ synthesis was measured after 30 min of incuba- 
tion by radio-immunoassay [13]. 
2.3. MAP kinase assay 
WI-38 lung fibroblasts were seeded into 6-well plates, grown to con- 
fluency and then incubated in serum-free medium for 18 h. The cells 
were then incubated with vehicle, anandamide, or PMA. The cell mon- 
olayers were washed with KRH and harvested inhypotonic lysis buffer 
(25 mM HEPES, pH 7.4, 5 mM ethylenediamine tetraacetic a id, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM Na-orthovanadate, 10,ug/ml 
leupeptin). The cell extracts were clarified by centrifugation for 10 rain 
at 12,000 × g. The MAP kinase activity in the supernantant fraction was 
measured using a synthetic peptide substrate based on the sequence 
surrounding the EGF receptor phosphorylation site Thr-669 [20]. MAP 
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kinase activity was also examined using an in-gel kinase assay with 
myelin basic protein (MBP) as the substrate [21]. Al l  
2.4. Western blotting 
Immunoblot analyses were performed after electrophoretic ransfer 
onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore 
Corp.). The membranes were probed consecutively with the monoclo- 
nal anti-phosphotyrosine antibody PY-20 (ICN) and the monoclonal 
ERKI/2 antibody #107 [22]. Immunecomplexes were detected by en- 
hanced chemiluminescence (Amersham International PLC). 
3. Results 
We investigated the effect of anandamide on arachidonic 
acid release using WI-38 human fetal lung fibroblasts pre-la- 
beled with [3H]arachidonic acid. Treatment with anandamide 
caused a concentrat ion-dependent increase in the release of 
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Fig. 1. Anandamide stimulates the production of arachidonic acid and 
prostaglandin E 2 (PGE2) in human WI-38 lung fibroblasts. The fibro- 
blasts were incubated for 10 min with vehicle (DMSO) or with increas- 
ing concentrations of anandamide for 10 min prior to measurement of 
the release of arachidonic acid (A) and PGE2 (B). The effect of treat- 
ment (10 min) with vehicle (DMSO), or with 8 #M anandamide, 
ethylarachidonate (EthylAA) or arachidonic acid (AA) on [3H]arachi- 
donic acid release is shown (C). The data are presented as the 
mean + S.D. of triplicate determinations. 
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Fig. 2. Anandamide stimulates MAP kinase activity. WI-38 fibroblasts 
were incubated for 10 min with vehicle (DMSO), the indicated concen- 
trations of anandamide or 100 nM PMA (A) or with 8 pM anandamide 
for the indicated times (B). MAP kinase activity was measured using 
a synthetic peptide substrate. The data are presented as the 
mean + S.D. of triplicate determinations. Insert: the cells were incu- 
bated for 10 min with vehicle (DMSO), 8 #M anandamide, or 100 nM 
PMA. MBP, MAP kinase activity was measured using an in-gel kinase 
assay with myelin basic protein (MBP) as a substrate. Tyr-P, Western 
blot analysis using an anti-phosphotyrosine a tibody. ERK2, Western 
blot analysis using an anti-ERKl/2 antibody. 
[3H]arachidonic acid and its metabolites (Fig. 1A). A similar 
increase was not observed when the cells were incubated with 
the anandamide analog ethylarachidonate or arachidonic acid 
(Fig. 1C). Arachidonic acid is a precursor for eicosanoid bio- 
synthesis. Previous studies have demonstrated that prosta- 
glandin E2 (PGE2) is the major eicosanoid synthesized by WI-38 
cells [13]. We therefore xamined the effect of anandamide on 
PGE2 biosynthesis. It was observed that anandamide caused a 
concentrat ion-dependent increase in PGE2 product ion by the 
cells (Fig. 1B). Together, these observations establish that an- 
andamide increases de novo eicosanoid biosynthesis. 
The effect of anandamide on MAP kinase activity was exam- 
ined using a synthetic peptide substrate based on the sequence 
surrounding the EGF receptor phosphorylat ion site Thr-669 
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Fig. 3. Anandamide activates cPLA 2. The electrophoretic mobility shift associated with cPLA 2 activation was examined by Western blot analysis 
using an anti-cPLA2 antibody. The anandamide ose response was investigated byincubation of WI-38 fibroblasts with increasing concentrations 
of anandamide orwith 100 nM PMA for 10 min. The time course was examined by treatment ofthe cells with 8/aM anandamide for the indicated 
times. 
[20]. Treatment of WI-38 fibroblasts with increasing doses of 
anandamide caused MAP kinase activation (Fig. 2A). At the 
highest concentration f anandamide t sted, MAP kinase activ- 
ity was approximately 60% of that found with 100 nM phorbol 
myristate acetate (PMA). MAP kinase activation by anan- 
damide was rapid with maximal activity at 10 min followed by 
a decline at later times (Fig. 2B). The stimulation of MAP 
kinase by anandamide was confirmed using an in-gel kinase 
assay with myelin basic protein as a substrate (Fig. 2A, inset). 
Immunoblot analysis demonstrated that the major MAP kinase 
isoform expressed by WI-38 cells is ERK2 and that anan- 
damide increased ERK2 tyrosine phosphorylation (Fig. 2A, 
inset). As tyrosine phosphorylation is required for ERK2 acti- 
vation [19,23], the observation of increased ERK2 tyrosine 
phosphorylation i  anandamide-treated c lls provides trong 
additional evidence for MAP kinase activation. 
Anandamide is rapidly metabolized by a membrane-associ- 
ated amidase [24]. A significant question is therefore whether 
anandamide or a metabolite ofanandamide mediates the effects 
on arachidonic acid release and MAP kinase activation (Figs. 
1 and 2). To examine this question we investigated the effect 
of phenylmethylsulfonyl fluoride, a potent inhibitor of the ami- 
dase that degrades anandamide [24]. Treatment of WI-38 cells 
with 1 mM phenylmethylsulfonyl fluoride was found to poten- 
tiate the stimulation of arachidonic acid release, PGE2 produc- 
tion, and MAP kinase activity by anandamide (data not 
shown). This observation is consistent with the hypothesis that 
there is a direct signaling role for anandamide. 
One substrate for activated MAP kinase is cPLA 2 [19]. We 
have demonstrated that MAP kinase phosphorylates cPLA2 at 
a single site, Ser-505, and that this phosphorylation increases 
the enzymatic activity ofcPLAz and results in a marked electro- 
phoretic mobility-shift during SDS-PAGE [18]. The stimulation 
of both MAP kinase and arachidonic acid release (Figs. 1 and 
2) suggests that anandamide activates cPLA 2. We therefore 
examined cPLA2 in cells treated with anandamide or PMA. Fig. 
3 shows that anandamide caused a time- and concentration- 
dependent redistribution of cPLA2 from the basal state to the 
phosphorylated and activated form that exhibits reduced elec- 
trophoretic mobility [18]. The conversion of cPLA z to the acti- 
vated form caused by anandamide was similar to that caused 
by 100 nM PMA (Fig. 3). 
The cloned THC receptors have seven transmembrane-span- 
ning domains typical of G protein-coupled receptors [3,4]. Ac- 
tivation of MAP kinase and increased arachidonic acid release 
caused by receptors coupled to heterotrimeric G proteins has 
been shown in previous studies to be inhibited by pertussis 
toxin [25-28]. We therefore investigated the effect of pertussis 
toxin on WI-38 fibroblasts. No significant effect of pertussis 
toxin on EGF-stimulated MAP kinase activation was detected 
(data not shown). However, treatment ofthe cells with pertussis 
toxin was found to block the effect of anandamide on MAP 
kinase activation and arachidonic acid release (Fig. 4). This 
sensitivity to pertussis toxin has also been observed for the 
regulation of cAMP levels and N-type calcium channels by 
anandamide [6,10]. Together, these data are consistent with the 
hypothesis that the cellular esponse to anandamide is mediated 
by a G protein-coupled receptor. 
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Fig. 4. A G protein pathway mediates the activation of MAP kinase 
and cPLA2 by anandamide. The effect of pertussis toxin-treatment on 
anandamide-stimulated rachidonic acid release (A) and MAP kinase 
activity (B) was examined. Confluent WI-38 cells were incubated with- 
out (-PTX) or with (+ PTX) 200 ng/ml pertussis toxin (Calbiochem- 
Novabiochem Corp.) for 18 h. The cells were then incubated for 10 min 
with vehicle (Control) or 8/aM anandamide. The data are presented as 
the mean +_ S.D. of triplicate determinations. 
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4. Discussion 
4.1. Signal transduction by anandamide mediated by a G protein- 
coupled receptor 
Two cannabinoid receptors have been molecularly cloned. 
The amino acid sequence of these receptors indicates that they 
are members of the seven transmembrane -spanning domain 
class of G protein-coupled receptors [3,4]. Interestingly, the 
tissue distribution of these receptors is distinct for each sub- 
type (highest expression in the brain [4] and spleen [3]). Addi- 
tional receptor sub-types expressed in other tissues remain to 
be identified. 
Examination of the function of the brain receptor [4] ex- 
pressed in heterologous cells indicates that it does not mediate 
the effects of anandamide on arachidonic acid metabolism 
[10,11]. The effect of anandamide on arachidonic acid metabo- 
lism in this particular model could therefore be mediated by a 
non-receptor mechanism. However, the finding that pertussis 
toxin inhibits anandamide-stimulated arachidonic acid release 
indicates that a G protein-coupled receptor is likely to mediate 
the effects of anandamide in human WI-38 fibroblasts (Fig. 4). 
Further studies are required to molecularly characterize the 
receptor(s) that mediates the effects of anadamide on MAP 
kinase activation and arachidonic acid release in human WI-38 
fetal lung fibroblasts. 
4.2. Anandamide activates the MAP kinase signal transduction 
pathway 
The newly described endogenous cannabimimetic anan- 
damide is likely to be a physiologically significant regulatory 
molecule [5]. The finding that anandamide activates the MAP 
kinase signal transduction pathway is consistent with this hy- 
pothesis (Fig. 2). Importantly, MAP kinase activation provides 
a mechanism for signal transduction from cell surface THC 
receptors to targets located within multiple cellular compart- 
ments, including the cell surface, the cytoskeleton, and the 
nucleus [19]. MAP kinase activation may therefore represent a 
primary response of cells to anandamide. Indeed, it is likely that 
the MAP kinase signal transduction pathway mediates the ef- 
fects of anandamide on arachidonic acid metabolism (Fig. 3). 
Incubation of cultured cells with anandamide causes in- 
creased arachidonic acid release. The mechanism of this re- 
sponse can be accounted for by the activation of one or more 
PLA2 isoforms [29]. One of these isoforms, cPLA2 [16,17], is 
activated by the MAP kinase signal transduction pathway [18]. 
Significantly, the addition of anandamide to WI-38 fibroblasts 
causes activation of MAP kinase (Fig. 2) and cPLA2 (Fig. 3). 
Together, these observations uggest that MAP kinase and 
cPLA2 mediate, at least in part, the effect of anandamide to 
cause increased arachidonic acid release. 
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